Synthesis and Evaluation of Mycobacterial ClpP1P2 Inhibitors

Vol. 1, 2019 - 111689
Poster only
Favorite this paper
How to cite this paper?
Abstract

Despite numerous drugs for treatment of tuberculosis (TB) infections being available it remains a devastating disease. New drugs are desperately needed to shorten TB treatment to improve patient compliance and drug resistance. One promising new target for TB treatment is caseinolytic protease (ClpP1P2). Based on the similarity of ClpP1P2 to the human proteasome, we propose using known proteasome inhibitors as starting points for a structurally enabled ClpP1P2 hit-to-lead campaign. Importantly, our efforts will focus on proteasome inhibitors identified as active in whole-cell Mycobacterium tuberculosis (Mtb) assays. Docking of these cell-active compounds into the Mtb ClpP1P2 active site has identify putative binding modes which will aid the design of more potent inhibitors as well as inhibitors with suitable selectivity for Mtb ClpP1P2 over mammalian cells. In this work a literature Mtb ClpP1P2 enzymatic assay was used to determine on-target activity of the synthesized inhibitors and to correlate with whole-cell Mtb activity.

Institutions
  • 1 Drug Discovery and Development Centre (H3-D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa
Track
  • 2. Medicinal Chemistry of Synthetic Compounds
Keywords
Mycobacterium tuberculosis
ClpP1P2
Proteasome
Target based drug discovery